Abstract
After a mean follow-up of 34 months (range 6-161 months) 52% of 162 patients with refractory epilepsy (mostly with partial seizures) continue on add-on Vigabatrin treatment. Ten percent are seizure-free and an additional 12% achieved a greater than 75% reduction in seizures frequency. None of the patients with generalized epilepsies responded. Only 11% discontinued treatment because of adverse effects, usually within the first 6 months.
Translated title of the contribution | Long term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy |
---|---|
Original language | Italian |
Pages (from-to) | 23-25 |
Number of pages | 3 |
Journal | Bollettino - Lega Italiana contro l'Epilessia |
Issue number | 99 SUPPL. 1 |
Publication status | Published - 1997 |
ASJC Scopus subject areas
- Clinical Neurology